More Bad Trial News For AutoImmune
AutoImmune has suffered another setback with the announcement ofpreliminary results from two Phase II trials of its oral tolerance product for arthritis, Colloral (collagen).
Last month, the firm's lead compound for multiple sclerosis, Myloral (myelin basic protein) produced disappointing results in a Phase III trial (Marketletter April 28), leading to speculation that the company's faith in the potential of inducing oral tolerance to antigens as a means of treating autoimmune disease might be misguided.
Both the Phase II Colloral trials demonstrated positive trends for Colloral, but could not show statistical significance versus placebo. "Based on these data and previous trials, the company believes that Colloral has therapeutic benefit, but may require further development before entering Phase III trials," said AutoImmune in a statement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze